Ipamorelin (IPA)

Growth Hormone Clinical trials

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels, making it one of the safest GH-releasing peptides available.

Key Data

Research Status
Clinical trials
Half-Life
2 hours
Administration
Subcutaneous injection
Typical Dosage
100-300 mcg

Mechanism of Action

Selective GHRP receptor agonist, mimics ghrelin to stimulate pituitary GH release without affecting other hormones.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home